Long-term clinical benefit after highly active antiretroviral therapy in advanced HIV-1 infection, even in patients without immune reconstitution

International Journal of STD and AIDS

Volumn 12, Issue 9, 2001, Pages 573-581

  Arici, C ^a   Ripamonti, D ^a   Ravasio, V ^a   Maggiolo, F ^a   Rizzi, M ^a   Finazzi, M G ^a   Suter, F ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

AIDS; Clinical outcome; HAART; HIV infection; Immune reconstitution; Observational study; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; RITONAVIR; SAQUINAVIR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INFECTION RISK; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED COMPLEX; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INCIDENCE; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0034876419     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462011923741     Document Type: Article

References (38)

1. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy
2. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virological failure and adverse drug reaction
3. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
4. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality
5. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres
6. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
7. Predictors of optimal virological response to potent antiretroviral therapy
8. CD4 cell count at the third month of HAART may predict clinical failure
9. Long-lasting recovery in CD4 T-cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease
10. Risk of new AIDS diseases in people on triple therapy
11. Positive effect of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
12. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
13. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study
14. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort
15. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: Results from the EuroSIDA study
16. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection
17. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor
18. 1993 Revised Classification System for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
19. Effect of HAART on natural history of AIDS-related opportunistic disorders
20. Survival after introduction of HAART in people with known duration of HIV-1 infection
21. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy
22. The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection
23. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe
24. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy
25. Sex differences in HIV - Viral load and progression to AIDS
26. Sex difference in HIV-1 viral load and progression to AIDS
27. HIV disease in 854 women and men infected through injecting drug use and heterosexual sex and followed up to nine years from seroconversion
28. Sex difference in HIV-1 viral load and progression to AIDS
29. Gender is not a factor in serum human immunodeficiency virus type 1 RNA levels in patients with viremia
30. Lack of sex difference in CD4 to HIV-1 RNA viral load ratio
31. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo
32. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART)
33. Change in plasma HIV-RNA and CD4 lymphocyte counts in patients receiving highly active antiretroviral therapy
34. Discordant immunological and virological responses to HAART
35. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor
36. Editorial response: Discordance between virological, immunologic and clinical outcomes of therapy with protease inhibitors among human immunodeficiency virus-infected patients
37. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy
38. HIV-1 immunogen (Remune) stimulates HIV-specific T helper immune responses across clades including types C